Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)


Adoptive regulatory T-cell (Treg) therapy using autologous Tregs expandedex vivois a promising therapeutic approach which is currently being investigated clinically as a means of treating various autoimmune diseases and transplant rejection. Despite this, early results have highlighted the need for potent Tregs to yield a substantial clinical advantage. One way to achieve this is to create antigen-specific Tregs which have been shown in pre-clinical animal models to have an increased potency at suppressing undesired immune responses, compared to polyclonal Tregs. This mini review outlines where Treg therapy currently stands and discusses the approaches which may be taken to generate antigen-specific Tregs, including the potential use of chimeric antigen receptors (CARs), for future clinical trials.

Original languageEnglish
Pages (from-to)342-8
Number of pages7
JournalBiochemical Society Transactions
Issue number2
Publication statusPublished - 15 Apr 2016


Dive into the research topics of 'Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?'. Together they form a unique fingerprint.

Cite this